| Patent Number |
Title Of Patent |
Date Issued |
| 5767065 |
Use of interleukin-4 receptors to inhibit biological responses mediated by interleukin-4 |
June 16, 1998 |
| Mammalian Interleukin-4 receptor proteins find use in inhibiting biological activities of IL-4. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable |
| 5767064 |
Soluble type II interleukin-1 receptors and methods |
June 16, 1998 |
| Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed. Also disclosed are compositions and methods for regulating an IL-1 mediated immune or |
| 5763223 |
DNA encoding a cytokine that induces apoptosis |
June 9, 1998 |
| A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies |
| 5753203 |
CD30 ligand conjugates |
May 19, 1998 |
| There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells |
| 5747024 |
Vaccine adjuvant comprising interleukin-15 |
May 5, 1998 |
| Methods of enhancing a mammal's immune response to a vaccine antigen are disclosed. Interleukin-15 can be used as a vaccine adjuvant to enhance or potentiate the immune response to a vaccine. Compositions comprising an immunogenic amount of vaccine antigen and an immunogenicity-augmentin |
| 5738844 |
Cytokines that bind the cell surface receptor hek |
April 14, 1998 |
| Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that includ |
| 5728813 |
Antibodies directed against elk ligand |
March 17, 1998 |
| Antibodies to elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family. |
| 5726286 |
Isolated epstein-barr virus BZLF2 proteins that bind MHC class II beta chains |
March 10, 1998 |
| Isolated viral proteins, and pharmaceutical compositions made therefrom, are disclosed which are capable of binding to a .beta. chain of a Class II Major Histocompatibility Complex antigen, thereby functioning to inhibit an antigen-specific response. The viral proteins also have supe |
| 5717072 |
Antibodies that are immunoreactive with interleukin-4 receptors |
February 10, 1998 |
| Mammalian antibodies that are immunoreactive with Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, as well as antibodies that are immunoreactive with IL-4 |
| 5716805 |
Methods of preparing soluble, oligomeric proteins |
February 10, 1998 |
| There is disclosed a method of preparing a soluble mammalian protein by culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a zipper domain and a heterologous mammalian protein. |
| 5716623 |
Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules |
February 10, 1998 |
| Isolated viral proteins, and compositions made therefrom, are disclosed which are capable of binding to Class II Major Histocompatibility Complex antigen, thereby functioning to inhibit an antigen-specific response. The isolated viral proteins also act as superantigens. |
| 5712155 |
DNA encoding tumor necrosis factor-.alpha. and -.beta. receptors |
January 27, 1998 |
| Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed. |
| 5707616 |
Method for treating or preventing gastrointestinal disease with epithelium-derived T-cell factor |
January 13, 1998 |
| Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastr |
| 5677430 |
Antibodies directed against CD30 ligand |
October 14, 1997 |
| There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells |
| 5674704 |
Cytokine designated 4-IBB ligand |
October 7, 1997 |
| Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transfo |
| 5674492 |
Method of preventing or treating disease characterized by neoplastic cells expressing CD40 |
October 7, 1997 |
| There is disclosed a method of treating a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer. CD40 binding proteins include |
| 5670625 |
Elk ligand fusion proteins |
September 23, 1997 |
| elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family. |
| 5629285 |
Inhibitors of TNF-.alpha. secretion |
May 13, 1997 |
| Compounds and methods are disclosed that are useful in inhibiting the TNF-.alpha. converting enzyme (TACE) responsible for cleavage of TNF-.alpha. precursor to provide biologically active TNF-.alpha.. The compounds employed in the invention are peptidyl derivatives having active grou |
| 5627267 |
Cytokine designated elk ligand |
May 6, 1997 |
| elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family. |
| 5620889 |
Human anti-Fas IgG1 monoclonal antibodies |
April 15, 1997 |
| The present invention provides a panel of monoclonal antibodies and binding proteins which specifically bind to human Fas antigen. Some of the antibodies and binding proteins are capable of stimulating T cell proliferation, inhibiting binding of anti-Fas CH-11 monoclonal antibody to |
| 5616477 |
Fusion proteins comprising GM-CSF and antigens and their expression in yeast |
April 1, 1997 |
| Novel fusion proteins that enhance the immune response of an antigen are efficiently expressed and secreted by yeast host cells. The fusion proteins are recombinantly made by fusing the 3'-end of mature GM-CSF DNA sequence to the 5'-end of an antigen DNA sequence with or without a linker |
| 5605690 |
Methods of lowering active TNF-.alpha. levels in mammals using tumor necrosis factor receptor |
February 25, 1997 |
| A method for treating TNF-dependent inflammatory diseases in a mammal by administering a TNF antagonist, such as soluble TNFR. |
| 5599905 |
Interleukin-4 receptors |
February 4, 1997 |
| Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mamma |
| 5594106 |
Inhibitors of TNF-.alpha. secretion |
January 14, 1997 |
| Compounds and methods are disclosed that are useful in inhibiting the TNF-.alpha. converting enzyme (TACE) responsible for cleavage of TNF-.alpha. precursor to provide biologically active TNF-.alpha.. The compounds employed in the invention are peptidyl derivatives having active grou |
| 5591630 |
Monoclonal antibodies that bind interleukin-15 receptors |
January 7, 1997 |
| There are disclosed Interleukin-15 Receptor (IL-15R) proteins, DNAs and expression vectors encoding IL-15R, and processes for producing IL-15R as products of recombinant cell cultures. Also disclosed are monoclonal antibodies that bind Interleukin-15 receptors. |
| 5589456 |
Granulocyte-colony stimulating factor receptors |
December 31, 1996 |
| Mammalian granulocyte-colony stimulating factor (G-CSF) receptor proteins, DNAs and expression vectors encoding mammalian G-CSF receptors, and processes for producing mammalian G-CSF receptors as products of recombinant cell culture, are disclosed. |
| 5576191 |
Cytokine that binds ST2 |
November 19, 1996 |
| ST2 ligand polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing ST2 ligand polypeptides. The ST2 ligand polypeptide binds to a receptor that is expressed on cell types that include certain Hodgkin's Disease-derived tum |
| 5574138 |
Epithelium-derived T-cell factor |
November 12, 1996 |
| Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastr |
| 5573924 |
CD27 ligand |
November 12, 1996 |
| CD27 ligand (CD27L) polypeptide and DNA sequences, vectors and transformed host cells useful in providing CD27L polypeptides. The CD27L polypeptide binds to the CD27 receptor. |
| 5565321 |
Detection of mutations in a CD40 ligand gene |
October 15, 1996 |
| There is disclosed a method of detecting a mutation in a CD40 ligand gene, comprising isolating nucleic acid from an individual, selectively amplifying nucleic acid derived from the CD40 ligand gene, and analyzing the amplified nucleic acid to determine if there is a mutation (or mut |
| 5557535 |
Method and system for protein modeling |
September 17, 1996 |
| A method in a computer system for modeling a three-dimensional structure of a model protein is provided. In a preferred embodiment, the modeling is based upon a three-dimensional structure of a template protein and an amino acid sequence alignment of the model protein and the template |
| 5552303 |
DNA encoding epithelium-derived T-cell factor |
September 3, 1996 |
| There is disclosed a mammalian epithelium-derived T-cell factor (EFT) polypeptide, derivatives thereof, DNA sequences, recombinant DNA molecules and transformed host cells that produce ETF polypeptides. More particularly, this invention provides isolated mammalian ETF polypeptides an |
| 5543320 |
Antibodies to interleuken-7 receptors |
August 6, 1996 |
| Mammalian Interleukin-7 receptor proteins, DNAs and expression vectors encoding mammalian IL-7 receptors, antibodies to mammalian Interleukin 7 receptors and processes for producing mammalian IL-7 receptors as products of recombinant cell culture, are disclosed. |
| 5538863 |
Expression system comprising mutant yeast strain and expression vector encoding synthetic signal |
July 23, 1996 |
| A novel strain of Saccharomyces cerevisiae is useful as a host cell in the production of recombinant proteins. The novel S. cerevisiae cells transformed with a recombinant expression vector encoding a desired heterologous protein, preferably fused to a suitable N-terminal signal pept |
| 5538863 |
Expression system comprising mutant yeast strain and expression vector encoding synthetic signal |
July 23, 1996 |
| A novel strain of Saccharomyces cerevisiae is useful as a host cell in the production of recombinant proteins. The novel S. cerevisiae cells transformed with a recombinant expression vector encoding a desired heterologous protein, preferably fused to a suitable N-terminal signal pept |
| 5516658 |
DNA encoding cytokines that bind the cell surface receptor hek |
May 14, 1996 |
| Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that includ |
| 5512457 |
Cytokine designated elk ligand |
April 30, 1996 |
| elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family. |
| 5492888 |
Method of using soluble human interleukin-1 receptors to suppress immune responses |
February 20, 1996 |
| Methods of using shuIL-1Rs to suppress IL-1 mediated immune responses in a mammal. |
| 5488032 |
Method of using soluble human interleukin-1 receptors to suppress inflammation |
January 30, 1996 |
| Methods of using shulL-1Rs to suppress IL-1 mediated inflammation in a mammal. |
| 5484887 |
Homogeneous interleukin 1 |
January 16, 1996 |
| Interleukin 1 has been purified by use of various techniques including ion exchange chromatography and dye-ligand affinity chromatography. By these techniques, interleukin 1 has been purified to homogeneity. The high purification of interleukin 1 has enabled the amino acid composition of |
| 5480981 |
CD30 ligand |
January 2, 1996 |
| There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells |
| 5464938 |
Isolated viral protein TNF antagonists |
November 7, 1995 |
| Isolated viral proteins, and pharmaceutical compositions made therefrom, are disclosed which are capable of binding to cytokines, thereby functioning as cytokine antagonists. Also disclosed are processes for preparing isolated vital protein cytokine antagonists. |
| 5464937 |
Type II Interleukin-1 receptors |
November 7, 1995 |
| Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed. |
| 5463029 |
Purification of fusion proteins comprising GM-CSF and IL-3 |
October 31, 1995 |
| A process for purifying a fusion protein comprising GM-CSF and IL-3 is disclosed. |
| 5457035 |
Cytokine which is a ligand for OX40 |
October 10, 1995 |
| There is disclosed a polypeptide (OX40-L) and DNA sequences, vectors and transformed host cells useful in providing OX40-L polypeptides. More particularly, this invention provides isolated murine OX40-L polypeptides that bind to the extracellular binding region of OX40. |
| 5453937 |
Method and system for protein modeling |
September 26, 1995 |
| A method in a computer system for modeling a three-dimensional structure of a model protein is provided. In a preferred embodiment, the modeling is based upon a three-dimensional structure of a template protein and an amino acid sequence alignment of the model protein and the template |
| 5447860 |
Tyrosine kinase |
September 5, 1995 |
| A novel receptor protein tyrosine kinase named ork (orphan receptor tyrosine kinase) is identified and characterized. cDNA encoding the ork protein is inserted into an expression vector for production of the protein via recombinant DNA technology. The ork cDNA, when transfected into |
| 5426048 |
DNA encoding a fusion receptor for oncostatin M and leukemia inhibitory factor |
June 20, 1995 |
| A receptor protein comprising a gp130 polypeptide linked to a single-chain leukemia inhibitory factor receptor (LIF-R) polypeptide is capable of binding both oncostatin M and leukemia inhibitory factor (LIF). The receptor protein binds LIF with greater affinity than does the single-c |
| 5422248 |
DNA sequences encoding granulocyte-colony stimulating factor receptors |
June 6, 1995 |
| Mammalian granulocyte-colony stimulating factor (G-CSF) receptor proteins, DNAs and expression vectors encoding mammalian G-CSF receptors, and processes for producing mammalian G-CSF receptors as products of recombinant cell culture, are disclosed. |
| 5420247 |
Leukemia inhibitory factor receptors and fusion proteins |
May 30, 1995 |
| Leukemia inhibitory factor receptor (LIF-R) proteins, DNAs and expression vectors encoding LIF-R, and processes for producing LIF-R as products of recombinant cell culture, are disclosed. |
